BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting
December 04, 2017 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...
BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111
November 13, 2017 16:05 ET
|
BeiGene, LTD.
Initiates global Phase 3 trial of BGB-3111 compared to bendamustine and rituximab (BR) in treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patientsInitiates global...
BeiGene Reports Third Quarter 2017 Financial Results
November 13, 2017 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Nov. 13, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative...